Log In
BCIQ
Print this Print this
 

glecaprevir/pibrentasvir (ABT-493 plus ABT-530)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionFixed-dose oral combination of glecaprevir (ABT-493), a next-generation HCV NS3/4A protease inhibitor, and pibrentasvir (ABT-530), a next-generation HCV NS5A protein inhibitor
Molecular Target HCV NS3/4A protease complex ; HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1 infection in patients who failed prior therapy with direct-acting antivirals (DAAs); Treat chronic HCV genotype 3 infection; Treat chronic HCV genotypes 1 and 4-6 infection in patients who failed a prior direct-acting antiviral (DAA)-containing therapy; Treat chronic HCV genotypes 2-6 infection
Regulatory Designation U.S. - Breakthrough Therapy (Treat chronic HCV genotype 1 infection in patients who failed prior therapy with direct-acting antivirals (DAAs))
PartnerEnanta Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today